Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
Last trade$8.42
Day change$0.00 (0.00%)
Day range$8.10 – $8.47
Volume1,928,409
Market cap$3.15B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.15B
Price / earnings
—
Price / book
-2.37×
Price / sales
0.28×
EV / sales
1.92×
EV / EBITDA
5.02×
Profitability
Earnings per share
-$2.25
Return on assets
-3.3%
Return on equity
63.33%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-15.54×
Current ratio
1.56×
Quick ratio
1.22×
Cash ratio
0.52×
Cash flow
Price / cash flow
1.43×
Price / free cash flow
1.69×
Free cash flow
$1.87B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BHC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$2.94B
$2.85B
$2.52B
$2.8B
$2.68B
$2.53B
$2.26B
$2.56B
Cost of revenue
$735M
$772M
$738M
$798M
$750M
$764M
$701M
$727M
Gross profit
$2.21B
$2.08B
$1.79B
$2B
$1.93B
$1.77B
$1.56B
$1.83B
Selling, general and administrative
$834M
$907M
$861M
$882M
$795M
$894M
$867M
$820M
Research and development
$141M
$173M
$163M
$161M
$166M
$159M
$143M
$163M
Total operating expenses
$1.22B
$1.34B
$2.74B
$1.38B
$1.31B
$1.32B
$1.28B
$1.03B
Operating income
$983M
$740M
-$950M
$616M
$619M
$444M
$276M
$805M
Interest expense
-$398M
-$396M
-$402M
-$397M
-$412M
-$465M
-$330M
-$337M
Income before taxes
$597M
$348M
-$1.35B
$56M
$218M
$140M
-$47M
$209M
Income taxes
$151M
$88M
$77M
$159M
$37M
$12M
$39M
$111M
Net income
$446M
$260M
-$1.43B
-$103M
$181M
$128M
-$86M
$98M
Net income attributable to common shareholders
$436M
$258M
-$1.42B
-$112M
$179M
$148M
-$58M
$93M
EBITDA
$1.28B
$1.03B
$784M
$1.15B
$942M
$782M
$582M
$1.22B
Basic earnings per share
$1.16
$0.69
-$3.82
-$0.30
$0.48
$0.40
-$0.16
$0.25
Diluted earnings per share
$1.15
$0.68
-$3.82
-$0.29
$0.48
$0.40
-$0.16
$0.25
Recent news
Company coverage with links to the original publishers.
Zacks Premium offers investment research tools including Style Scores (Value, Growth, Momentum, and VGM) designed to work alongside the Zacks Rank system to help investors identify stocks with the highest probability of outperformance. The article highlights Bausch Health (BHC) as a stock to watch with a #3 Hold rank and top-tier Momentum and VGM Style Scores, noting 41.8% gains over four weeks.
Bausch Health Companies (BHC) raised its 2026 revenue guidance to $5.525-$5.625 billion and adjusted EBITDA to $3.225-$3.275 billion, citing sustained operational growth and stronger cash generation. However, the company warned that Q4 performance will be pressured by Xifaxan pricing changes and inventory adjustments, with an anticipated $400-500 million year-over-year net impact in 2027. BHC reduced net debt by $521 million in the quarter and achieved 14 consecutive quarters of revenue and EBITDA growth.
Bausch Health Companies reported Q3 adjusted EPS of $1.77, surging 52.6% year-over-year and beating consensus estimates. Revenues rose 9.7% to $2.94 billion, driven by strong Salix performance with Xifaxan sales up 16%. The company raised its 2026 revenue and EBITDA guidance and authorized a $50 million share repurchase program. However, Solta Medical showed organic revenue decline and Bausch + Lomb came in slightly below expectations.
Bausch Health reported quarterly earnings of $1.77 per share, significantly beating the consensus estimate of $1.08 and surpassing revenue expectations. The company received a Zacks Rank #2 (Buy) rating despite underperforming the S&P 500 by 22% year-to-date. Amphastar Pharmaceuticals is expected to report lower earnings with a -16.1% year-over-year decline.
Bausch Health reported $2.94 billion in revenue for Q3 2026, exceeding consensus estimates by 7.11% with a 9.7% year-over-year increase. The company delivered an EPS of $1.77, significantly beating the consensus estimate of $1.08 by 63.89%. Strong performance was driven by Salix revenues (+16.1% YoY), Solta Medical (+17.9% YoY), and Diversified Products segments, though Bausch + Lomb Surgical revenues fell slightly short of estimates.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Nov 10, 2010
$1.00
Dec 22, 2010
special
Aug 30, 2010
$0.095
Oct 4, 2010
recurring
May 28, 2010
$0.095
Jul 5, 2010
recurring
Mar 4, 2010
$0.09
Apr 5, 2010
recurring
Nov 30, 2009
$0.09
Jan 4, 2010
recurring
Stock splits
Historical share-structure events and their execution dates.